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Abstract  22 
Bacitracin is a cell wall targeting antimicrobial with clinical and agricultural 23 
applications. With the growing mismatch between antimicrobial resistance and 24 
development, it is essential we understand the molecular mechanisms of 25 
resistance in order to prioritise and generate new effective antimicrobials. BcrR 26 
is a unique membrane-bound one-component system that regulates high-level 27 
bacitracin resistance in Enterococcus faecalis. In the presence of bacitracin, 28 
BcrR activates transcription of the bcrABD operon conferring resistance 29 
through a putative ATP-binding cassette (ABC) transporter (BcrAB). BcrR has 30 
three putative functional domains, a N-terminal helix-turn-helix DNA-binding 31 
domain, an intermediate oligomerisation domain, and a C-terminal 32 
transmembrane domain. However, the molecular mechanisms of signal 33 
transduction remain unknown. Random mutagenesis of bcrR was performed to 34 
generate loss and gain of function mutants using transcriptional reporters fused 35 
to the target promoter PbcrA. Fifteen unique mutants were isolated across all 36 
three proposed functional domains, comprising fourteen loss of function and 37 
one gain of function. The gain of function variant (G64D) mapped to the putative 38 
dimerisation domain of BcrR, and functional analyses indicated that the G64D 39 
mutant constitutively expresses the PbcrA-luxABCDE reporter. DNA-binding and 40 
membrane insertion were not affected in the five mutants chosen for further 41 
characterisation. Homology modelling revealed putative roles for two key 42 
residues (R11 and S33) in BcrR activation. Here we present a new model of BcrR 43 
activation and signal transduction, providing valuable insight into the functional 44 
characterisation of membrane-bound one-component systems and how they 45 
can co-ordinate critical bacterial responses, such as antimicrobial resistance.  46 
INTRODUCTION 47 
One-component regulatory systems containing both a sensory domain and DNA-48 
binding domain dominate signal transduction systems in bacteria and archaea [1]. 49 
They regulate important cellular functions such as antimicrobial resistance, metal 50 
homeostasis, carbon and amino acid metabolism, and quorum sensing [2]. They are 51 
both evolutionarily older and more widely distributed than their two-component 52 
counterparts [1, 2]. However, they are vastly understudied, particularly those that are 53 
membrane-bound [1]. 54 
BcrR is a unique one-component regulator of high-level zinc-bacitracin (bacitracin) 55 
resistance in Enterococcus faecalis [3]. BcrR consists of three proposed functional 56 
domains, a N-terminal helix-turn-helix (HTH) DNA-binding domain, an intermediate 57 
oligomerisation domain and a C-terminal transmembrane domain [4]. We have 58 
previously shown BcrR directly detects bacitracin in vitro [5]. Intrinsic tryptophan 59 
fluorescence of BcrR was reduced in the presence of bacitracin, suggesting a direct 60 
interaction between BcrR and bacitracin [5]. Previous electrophoretic mobility shift 61 
assays (EMSAs) and PbcrA-lacZ reporter assays have shown that BcrR is constitutively 62 
bound to two sets of inverted DNA repeat sequences upstream of its resistance 63 
operon, bcrABD, but requires bacitracin for activation [4]. BcrR is therefore thought to 64 
exist as dimers in its inactive state, with oligomerisation (likely dimer-dimer formation) 65 
induced upon addition of bacitracin. The DNA-binding footprint of BcrR on the bcrABD 66 
promoter region does not change between induced and uninduced states, suggesting 67 
a conformational change in BcrR, and/or subtle changes in local DNA topology are 68 
required to initiate bcrABD expression [5]. How BcrR binds bacitracin and transduces 69 
the signal to initiate bcrABD expression remains unknown. 70 
The first two genes in the target operon, bcrAB, encode a putative heterodimeric ABC 71 
efflux transporter (BcrAB) that is essential for high-level bacitracin resistance [3]. This 72 
transporter is distinct from other ABC transporters (i.e. BceAB) that are frequently 73 
associated with drug removal in Firmicute bacteria, such as Enterococcus and 74 
Bacillus [3, 6–8], in that its expression is regulated by a one-component rather than 75 
two-component system [8–10]. The third target gene, bcrD, encodes an 76 
uncharacterised undecaprenyl pyrophosphate phosphatase that is not necessary for 77 
high-level resistance [3].  78 
The aim of this study was to identify key residues critical for BcrR function using 79 
random mutagenesis and reporter assays, to further our understanding of the role 80 
these three functional domains play in one-component signal transduction systems. 81 
Fifteen unique mutations were identified, fourteen loss of function (LOF) and one gain 82 
of function (GOF). The G64D GOF mutant was localised to the putative dimerisation 83 
domain of BcrR. The transcription activation profile of the GOF G64D mutant was 84 
determined using the PbcrA-luxABCDE reporter in order to understand its ability to 85 
activate bcrABD in the absence of the inducer, bacitracin. A further four mutants (in 86 
addition to G64D) spanning all three functional domains were chosen for detailed 87 
characterisation of cellular localisation and DNA-binding capability. A three-88 
dimensional model was constructed of the DNA-binding domain (DBD) to further 89 
elucidate the role of the DBD mutants in BcrR function. 90 
METHODS 91 
Bacterial strains and growth conditions 92 
All strains used in this study are listed in Table S1, the Bacillus subtilis SGB37 strain 93 
was used as a heterologous host for transformation and expression of mutant bcrR, 94 
and BcrR activity assays. Genomic DNA was isolated from the E. faecalis strain 95 
AR01/DGVS and used as a template for PCR amplification of bcrR. Escherichia coli 96 
strains DH10B and C41(DE3) were used for cloning and protein production, 97 
respectively. E. coli and B. subtilis were routinely grown in lysogenic broth (LB) media 98 
at 37˚C overnight (200 r.p.m), while E. faecalis was grown in brain heart infusion (BHI) 99 
media at 37˚C with no agitation. For protein production, E. coli C41(DE3) was grown 100 
in 2 × yeast extract and tryptone (2 × YT) at 37˚C (200 r.p.m), unless otherwise stated. 101 
B. subtilis was transformed by natural competence as previously described [11]. 102 
Selective media contained ampicillin (amp; 100 μg ml-1 for E. coli), chloramphenicol 103 
(cm; 5 μg ml-1 for B. subtilis), kanamycin (kan; 10 μg ml-1 for B. subtilis), and 104 
spectinomycin (spec; 100 μg ml-1 for B. subtilis), where required. Bacitracin (bac; 0.5 105 
μg ml-1 for B. subtilis), xylose (xyl; 0.2% (w/v) for B. subtilis), and 5-bromo-4-chloro-3-106 
indolyl β-ᴅ-galactopyranoside (X-gal; 100 μg ml-1 for B. subtilis) were added to LB agar 107 
to select for LOF and GOF bcrR mutants. All solid media contained 1.5% (w/v) agar. 108 
Growth was measured as an optical density at 600 nm (OD600) (Jenway 6300 109 
Spectrophotometer).  110 
Hydroxylamine mutagenesis of bcrR 111 
Full length bcrR was previously cloned into the xylose-inducible plasmid pES701 (pXT-112 
bcrR) (Table S1) [12]. The pXT-bcrR plasmid was randomly mutagenised by 113 
incubation with the chemical mutagen hydroxylamine hydrochloride (HA) (1.25 mg per 114 
μg of DNA) in sodium phosphate buffer (f/c 50 mM sodium phosphate pH 7.0, 100 mM 115 
NaCl, 25 mM EDTA) at 75˚C for 15 min (Fig. 1). Mutated pXT-bcrR (mutbcrR) plasmid 116 
was purified by gel electrophoresis purification using the illustraTM GFXTM PCR DNA 117 
and gel band purification kit (GE Healthcare) (Table S1). The plasmid mutbcrR was 118 
used to transform B. subtilis strain SGB37 (harbouring PbcrA-lacZ) and B. subtilis strain 119 
SGB273 (harbouring PbcrA-luxABCDE), plated on LBspec agar and screened for LOF or 120 
GOF [11].  121 
Isolation of LOF and GOF bcrR mutants 122 
A modified protocol of traditional blue-white screening was used to isolate colonies 123 
with BcrR LOF or GOF [12]. LOF mutants were identified as white colonies on 124 
LBbac,xyl,Xgal agar plates (i.e. white = LOF), due to their inability to produce active BcrR, 125 
and are therefore unable to initiate expression of the β-galactosidase reporter 126 
construct PbcrA-lacZ (Fig. 1 and Fig. S1). GOF mutants were identified as blue colonies 127 
on LBxyl/Xgal plates, due to their ability to produce active BcrR in the absence of its 128 
inducer (bacitracin) and subsequently initiate expression of the β-galactosidase (Fig. 129 
1 and Fig. S1). GOF mutants were also identified as luminescing colonies on LBxyl 130 
agar plates in a SGB273 background. Mutations in putative LOF and GOF mutants 131 
were verified by DNA sequencing using the primer pair pXT-check fwd and pXT-check 132 
rev (Table S2). 133 
β-galactosidase and luciferase assays 134 
β-galactosidase assays using the fluorogenic substrate 4-methylumbelliferyl β-ᴅ-135 
galactoside (MUG) were carried out on all integrative lacZ reporter strains to 136 
quantitatively verify BcrR loss and gain of function phenotypes. BcrR mutant and 137 
control strains were grown to an OD600 of 0.4 in LB broth containing 0.2% xylose. 138 
Samples (100 μl) were taken and placed in four wells of a 96-well microtitre plate for 139 
each replicate of each strain. Cultures were challenged with 0, 0.1, 0.5, and 1 μg ml-1 140 
of bacitracin for 1 h. Cell density was determined as a final OD600 using the Varioskan 141 
Flash Multimode Reader (Thermo Fisher Scientific) and plates were subsequently 142 
frozen at - 80˚C. Expression analysis was measured as previously described [12, 13]. 143 
An unpaired t-test was performed between the wild-type (WT) and vector control (NC), 144 
along with the WT and BcrR mutants at 1 μg ml-1 bacitracin to determine statistical 145 
significance of respective β-galactosidase activities (an adjusted p value of ≤ 0.05). 146 
Luciferase activities of WT and G64D mutant BcrR were assayed using a Varioskan 147 
Flash Multimode Reader (Thermo Fisher Scientific) as previously described, with the 148 
following modifications [12]. Cultures were grown in the presence or absence of xylose 149 
(0.2%) to an OD600 of 0.1 and plated onto a 96-well microtitre plate. Cultures were 150 
challenged with final bacitracin concentrations of 0, 0.1, 0.5, and 1 μg ml-1 for 2 h, with 151 
OD600 and luminescence measured every 20 min.  152 
Generation of wild-type and mutant BcrR protein expression constructs 153 
Wild-type BcrR and five BcrR mutants (R11K, S33L, G64D, E179K, and T183M) were 154 
selected for further investigation. BcrRFwd and HisBcrRRev primers were used to 155 
clone WT bcrR from E. faecalis strain AR01/DGVS into the IPTG-inducible expression 156 
vector pTrc99A to produce pBcrRHisWT (Table S1 and S2). A His6 tag was introduced 157 
at the C-terminus of BcrR for purification purposes. Respective mutations for each 158 
selected mutant were introduced into WT bcrR using site-directed mutagenesis and 159 
overlap extension PCR to create the five BcrR variants pBcrRHisR11K, pBcrRHisS33L, 160 
pBcrRHisG64D, pBcrRHisE179K, pBcrRHisT183M (Tables S1 and S2) [14]. Constructs were 161 
confirmed by DNA sequencing. Chemically competent E. coli C41(DE3) were 162 
transformed (by heat-shock) with pBcrRHisWT and mutant plasmids, to generate 163 
strains WT, R11K, S33L, G64D, E179K, and T183M for protein production and 164 
purification (Table S1). 165 
Cellular localisation of BcrR wild-type and mutant forms 166 
E. coli strains producing BcrR WT and BcrR mutant protein were grown in 2 × YTamp 167 
media. When cultures reached an OD600 of 0.6 – 0.8 expression was induced with 1 168 
mM IPTG and cells were grown for a further 2 h. Cells were harvested by low-speed 169 
centrifugation (15 min, 10,000 × g at 4˚C) and resuspended in lysis buffer (50 mM 170 
Tris/HCl, 5 mM MgCl2, pH 7.5). Cells were lysed by three passages through the 171 
Aminco French Press at 40 kpsi at 4˚C. Unbroken cells and debris were removed by 172 
low speed centrifugation (15 min, 10,000 × g at 4˚C) and the cell lysate underwent 173 
high speed centrifugation (90 min, 123,695 × g at 4˚C) to separate the membrane and 174 
cytosolic fractions. Supernatants were removed, and membrane pellets were 175 
resuspended in lysis buffer, both were stored at -20˚C.  176 
Protein concentrations in the cytoplasmic and membrane fractions were determined 177 
by DC Bradford (BioRad) using bovine serum albumin (BSA) as a standard. Protein 178 
samples (about 50 μg) of both membrane and cytoplasmic fractions were run on 179 
12.5% SDS-PAGE gel, 125 V for 1.5 h using the Laemmli-SDS buffering system, and 180 
protein was visualised by standard silver staining [15]. Western Blot analysis was used 181 
to confirm BcrRHis WT and BcrR mutant protein was the ~20 kDa protein observed in 182 
the membrane fraction. Western Blots were carried out using a previously described 183 
protocol with an anti-His antibody (Abcam ab1187) and visualised using the Odyssey 184 
Fc Imaging System (LI-COR® Biosciences) [4].    185 
Protein purification of WT and mutant BcrRHis, and reconstitution into 186 
liposomes 187 
All six BcrR variants underwent protein purification using a previously described 188 
method with the following modifications [4]. Overproduction of BcrR is toxic to E. coli, 189 
therefore to optimise protein yield, 750 ml E. coli cultures were grown in 2 L flasks in 190 
2 × YT media, supplemented with ampicillin, with agitation and aeration (200 r.p.m) at 191 
37˚C [4]. At OD600 1.5 - 2, the cultures were induced with 1 mM IPTG and incubated 192 
for a further 1 h. Cells were lysed by two passages through the Constant Systems Ltd 193 
Cell Disrupter at 31 kpsi and 4˚C. Membranes were stored at - 20˚C for BcrR 194 
solubilisation and purification the following day. Prior to solubilisation, membranes 195 
were washed with buffer A (20 mM sodium phosphate pH 7.5, 0.1 mM PMSF, 5 mM 196 
DTT, 500 mM sodium chloride) containing 0.5% sodium cholate and disrupted by 197 
sonication (20% Amp) on ice for 6 × 30 sec cycles with 1 min rest periods. Membranes 198 
were ultra-centrifuged at 150,000 × g for 45 min. Membranes were then solubilised 199 
with buffer A containing 1% n-dodecyl-β-ᴅ-maltoside (DDM) and disrupted by 200 
sonication (as above). Solubilised protein was ultra-centrifuged at 150,000 × g for 45 201 
min. The supernatant (solubilised BcrR) was stored on ice and solubilisation was 202 
repeated for optimal protein yield.  The supernatant was loaded onto a Ni2+ HisTrap 203 
HP column (5 ml) using an AKTA Prime Plus (GE Healthcare) pre-equilibrated with 204 
five column volumes of buffer A containing 0.5% DDM and 10% glycerol (buffer A*). 205 
Unbound sample was removed by washing with buffer A* and buffer B (buffer A* 206 
containing 500 mM imidazole) at a ratio of 80:20 (at a rate of 2 ml min-1). BcrRHis was 207 
eluted (at a rate of 1 ml min-1) at a buffer A*- buffer B ratio of 30:70 and collected in 208 
1ml fractions. Remaining protein was eluted in 100% buffer B. In all cases elution was 209 
monitored by absorption at 280 nm in Primeview. Fractions collected from the 30:70 210 
peak were analysed by SDS-PAGE and visualised with Coomassie G-250 (Bio-Rad) 211 
(Fig. S2. a - f). BcrR-containing fractions were pooled and placed in Snakeskin® 212 
Pleated Dialysis Tubing (3,500 MWCO) and dialysed in 100 volumes of buffer A 213 
containing 10% glycerol at 4˚C overnight with gentle stirring. Dialysed protein was 214 
analysed by SDS-PAGE and protein was quantified by DC Bradford (BioRad) using a 215 
BSA standard. Average final protein concentrations were 3.5 - 5 mg ml-1. 216 
BcrRHis WT and mutants were reconstituted into L-α-phosphotidyl-choline liposomes 217 
(Sigma P5638) for electrophoretic mobility shift assays. BcrRHis WT and mutant 218 
protein was added to lipid at a ratio of 1:20 (protein:lipid), Triton X-100 and BioBeads® 219 
(BioRad) were used to integrate BcrRHis into liposomes to create BcrRHis WT, R11K, 220 
S33L, G64D, E179K, and T183M proteoliposomes using a previously reported 221 
protocol [5]. Protein concentration was quantified by separating protein from lipid on a 222 
12.5% SDS-PAGE gel containing four times the normal amount of SDS, alongside a 223 
BSA protein standard (Fig. S3). 224 
Electrophoretic Mobility Shift Assays (EMSA) 225 
 EMSAs were used to determine DNA-binding capacity of each of the five BcrRHis 226 
variants to the PbcrA target promoter. PbcrA was amplified by PCR, using primers 227 
bcrA_EMSA_F and bcrA_EMSA_R to produce a 92 bp DNA probe. The forward 228 
primer, bcrA_EMSA_F was tagged at the 5’ end with a 5’IRDye700 fluorophore (LI-229 
COR® Biosciences/Integrated DNA Technologies) for visualisation at 700 nm (Table 230 
S2). Non-labelled competitor probe was amplified by PCR, using the primers 231 
bcrA_EMSA_F (without the IRDye700 label) and bcrA_EMSA_R (Table S2). Binding 232 
reactions were carried out using a previously described method with the following 233 
modifications: 1.9 ng (32 fmoles) of labelled DNA was used in all binding reactions, 234 
and reactions were carried out at molar ratios of BcrR:DNA  (0:1, 25:1, 50:1, and 235 
125:1) in the dark, at room temperature [4]. Reactions were run on pre-cooled and 236 
pre-run (120 V, 1 h) 6% native acrylamide gels (37.5:1 acrylamide:bisacrylamide) in 237 
0.5 TBE (40 mM Tris-HCl (pH 8.3), 45 mM boric acid, 1 mM EDTA) on ice in a dark 238 
room at 350 V for 25 min. Gels were visualised for 10 min at 700 nm using the 239 
Odyssey® Fc Imaging System (LI-COR® Biosciences) with minimum light exposure. 240 
BcrR three-dimensional structural model 241 
A three-dimensional model of the BcrR DNA-binding domain was predicted using the 242 
P22 c2 repressor protein, which has the highest homology to BcrR (34% identity) (PDB 243 
file: 3JXB), as a model in ProtMod (Godzik Lab, The Burnham Institute). Structural 244 
analysis and amino acid substitution was carried out using PyMOL (The PyMOL 245 
Molecular Graphics System, Version 1.7 Schrödinger, LLC) [16]. 246 
RESULTS AND DISCUSSION 247 
Isolation and characterisation of loss and gain of function mutations in BcrR 248 
Loss (LOF) and gain of function (GOF) BcrR mutants were identified using B. subtilis 249 
strain SGB37 as a heterologous host as previously described [12]. Mutant BcrR 250 
(mutbcrR) was integrated into the host genome alongside the reporter for BcrR activity 251 
PbcrA-lacZ (β-galactosidase), following successful transformation. LOF and GOF 252 
mutants were isolated using a modified blue-white screening protocol as previously 253 
described [12]. LOF mutants were white in the presence of bacitracin, due to their 254 
inability to activate PbcrA-lacZ expression, while GOF mutants were identified as blue 255 
colonies in the absence of bacitracin due to their ability to activate PbcrA-lacZ 256 
expression in the absence of bacitracin (Fig. 1 and Fig. S1).  257 
A total of 428 colonies were screened for loss and gain of BcrR function. The average 258 
loss of function frequency was 8.3% (data not shown). All loss and gain of function 259 
mutants were sequenced to identify point mutations responsible for their respective 260 
phenotype. A total of fifteen unique bcrR point mutants were isolated using the β-261 
galactosidase reporter (Table 1). Mapping to the BcrR protein sequence identified four 262 
substitutions in the predicted helix-turn-helix (HTH) DNA-binding domain (DBD) motif 263 
(R11K, T17M, T30I, and S33L), four in the putative oligomerisation domain (OGD) 264 
(P42L, S51F, G64S, and G64D), and seven in the transmembrane domain (TMD) – 265 
four in the putative first and second transmembrane helices (G88R, P101L, T123I, and 266 
G141D), and three in the second extracellular loop (E179K, P180S, and T183M) (Fig. 267 
2). A number of mutations were observed more than once, and all mutations conferred 268 
a LOF, except G64D which resulted in a GOF (Table 1). Only one GOF mutant was 269 
isolated using the luciferase reporter (PbcrA-luxABCDE). Coincidentally, this mutant 270 
carried the same G64D substitution as the β-galactosidase GOF mutant.  271 
Quantitative measurement and validation of BcrR mutant activity 272 
BcrR activity in each of the LOF and GOF mutants was quantitatively measured using 273 
β-galactosidase assays (Fig. 3). Fluorescence (MUG) emitted by β-galactosidase 274 
activity was measured for each mutant at a range of bacitracin concentrations (0, 0.1, 275 
0.5 and 1 μg ml-1) and compared to the BcrR wild-type (WT) and empty vector control 276 
(NC). All strains were grown in the presence of xylose (0.2%) to ensure bcrR 277 
expression. WT BcrR activity (PbcrA-lacZ expression) was dose-dependent and 278 
maximal activity was observed at 1 μg ml-1 bacitracin (2000 RFU) (Fig. 3). The vector 279 
control showed a negligible response with a maximal activity of 20 RFU (Fig. 3). 280 
Thirteen of the fourteen LOF mutants from all three protein domains showed similar 281 
activity to the vector control, validating their LOF phenotype (Fig. 3). The G64S mutant 282 
displayed higher activity than the rest of the LOF mutants but remained significantly 283 
lower than WT in the presence of bacitracin, and therefore remained classified as LOF 284 
(Fig. 3b). Interestingly, the GOF mutant (G64D) was still inducible by bacitracin and 285 
expression was 3-fold higher than the WT at 1 μg ml-1 bacitracin (Fig. 3b).  286 
To validate the genomic-phenotypic linkages of the BcrR point mutations, genomic 287 
DNA (gDNA) was isolated from three LOF BcrR mutant B. subtilis strains (S33L, 288 
G64S, and E179K), the GOF mutant (G64D) strain, and the WT strain (SGB43) (Table 289 
1 and Table S1) using a previously described protocol [11]. This was to provide a 290 
“clean” genetic background, and to absolve any chance the observed LOF phenotype 291 
was due to a loss of β-galactosidase activity, rather than the associated BcrR point 292 
mutation. Clonal cultures of the B. subtilis PbcrA-lacZ reporter strain (SGB37; Table S1) 293 
were independently transformed with gDNA from each of the stated strains. 294 
Transformants were plated on LB agar containing spectinomycin to select for uptake 295 
of the BcrR construct. Three clones for each BcrR variant were streaked on LBxyl,bac,Xgal 296 
agar to phenotypically confirm BcrR function (Fig. S1). BcrR presence was detected 297 
in all clones by colony PCR. The G64D GOF mutant appeared as blue colonies, which 298 
represents activated BcrR and are darker than the light blue WT, indicating an 299 
increased activation state in the G64D mutant (Fig. S1a – b). The colonies for the LOF 300 
mutants S33L, G64S, and E179K (Fig. S1c - e), appeared white in colour, which 301 
represents a lack of active BcrR, i.e. LOF. BcrR activity was quantified for each BcrR 302 
variant by β-galactosidase activity analysis using the fluorogenic substrate MUG. 303 
Activity for each BcrR variant was comparable to the original assay (Fig. 3 and Fig. 304 
S4). This suggests these are indeed bona fide loss and gain of function BcrR point 305 
mutations, further supported by the independent isolation of most point mutations on 306 
more than one occasion (see “Frequency” Table 1). 307 
The bacitracin activation profile of the BcrR gain of function mutant G64D 308 
Two substitutions were observed at the same residue G64 (S and D), resulting in both 309 
a LOF and GOF genotype respectively. This residue is localised to the putative 310 
oligomerisation domain of BcrR, and oligomeric state is believed to play an important 311 
role in BcrR activation [5]. The bcrA promoter consists of two sets of inverted repeats 312 
that are essential for BcrR binding, and BcrR is often observed in both the monomeric 313 
and dimeric form [4]. Previous findings suggest BcrR forms a tetrameric dimer-dimer 314 
complex upon activation by bacitracin, therefore we hypothesise G64 may play a 315 
critical role in the formation of this complex [4, 5]. To investigate this proposal further, 316 
we carried out a more detailed analysis of the G64D activation profile (Fig. 4).  317 
BcrR G64D activity was compared to WT BcrR using the integrative luciferase reporter 318 
construct PbcrA-luxABCDE in the B. subtilis strain SGB273. Luciferase activity was 319 
used in place of β-galactosidase due to its greater sensitivity to activated BcrR (as 320 
observed in the absence of bacitracin, Fig. 3b and 4a). A comparison of BcrR WT and 321 
G64D activity was carried out in the presence of xylose (0.2%) and at a range of 322 
bacitracin concentrations (0, 0.1, 0.5 and 1 μg ml-1). BcrR G64D activity was 323 
significantly higher than WT at 0 and 0.1 μg ml-1 of bacitracin (Fig. 4a and 4b), but 324 
there was no significant difference at 0.5 and 1 μg ml-1 of bacitracin (Fig. 4c and 4d). 325 
We hypothesise the G64D mutation stabilises BcrR at 0 and 0.1 μg ml-1 of bacitracin 326 
allowing for spontaneous activation and hyper-sensitivity upon addition of low levels 327 
of bacitracin, while WT requires bacitracin for activation. It is also likely that binding of 328 
bacitracin stabilises BcrR, and this may explain why we do not see a significant 329 
difference in G64D and WT activity at 0.5 and 1 μg ml-1 of bacitracin.  330 
In the B. subtilis heterologous host strains, BcrR expression in the integrative pXT-331 
bcrR plasmid is under the control of a xylose-inducible promoter cloned upstream of 332 
the bcrR gene. However, this promoter is known to be leaky [17]. Therefore, to ensure 333 
the observed G64D phenotype was not an artefact of high BcrR expression and to 334 
mimic low-level constitutive BcrR expression as observed in its native enterococcal 335 
environment [3], luciferase assays were repeated in the absence of xylose. This 336 
showed G64D activity was also significantly higher than WT at 0 and 0.1 μg ml-1 of 337 
bacitracin, but not at 0.5 or 1 μg ml-1 at low levels of BcrR expression (albeit at lower 338 
overall levels) (Fig. 5 a – d). This suggests the G64D mutation is of physiological 339 
significance for BcrR function in its native environment [3, 4].  340 
DNA-binding activity of BcrR mutants R11K, S33L, G64D, E179K and T183M 341 
Previous investigations have found that BcrR requires membrane localisation for DNA-342 
binding activity and function [4, 5]. Five BcrR mutants, R11K, S33L (from the DBD), 343 
G64D (oligomerisation domain), and E179K and T183M (localised to the second 344 
extracellular loop cluster of the TMD), were chosen for further functional 345 
characterisation. To determine whether these mutations influenced the DNA-binding 346 
capability of BcrR, EMSAs were performed with the bcrABD target promoter region 347 
(PbcrA) (Fig. 6a). A shift of the PbcrA DNA probe was observed for WT BcrR and all five 348 
BcrR mutants (Fig. 6 b – g). No shift was observed in the absence of BcrR (Fig. 6h, 349 
liposome-only control). However, auto-fluorescence of the liposomes was detected. 350 
To avoid introduction of experimental artefact, densitometric analyses were 351 
subsequently performed on the probe (Fig. 6b – g and Fig. S5). The densitometric 352 
data shows that upon addition of BcrR-containing proteoliposomes, the relative band 353 
intensity of the probe decreases (Fig. S5). In the BcrR WT and S33L mutant, this shift 354 
is concentration-dependent (Fig. S5). For the BcrR R11K, G64D, E179K, and T183M 355 
mutants, a complete band shift is observed at the lowest ratio of BcrR:DNA (25:1) (Fig. 356 
S5). A non-labelled competitor probe (of the same length and nucleotide sequence as 357 
IRDye700PbcrA) was able to displace the labelled PbcrA target probe at increasing 358 
concentrations, shown as an increase in free labelled probe and a decrease in bound 359 
probe (Fig. S6a, lanes 1 – 5). This additional control, alongside previous work that has 360 
shown BcrR proteoliposomes bind a site-specific probe [4, 5], confirms BcrR WT and 361 
all five BcrR mutants are able to specifically bind the target bcrA DNA probe. 362 
Molecular modelling of the BcrR DNA-binding domain and theoretical analysis 363 
of the DNA-binding domain mutants 364 
The DBD mutants R11K and S33L were able to recognise and bind to the bcrABD 365 
promoter, despite conferring a loss of BcrR function. Therefore, in order to further 366 
understand the implications of the R11K and S33L substitutions on BcrR function, a 367 
three-dimensional model of the DBD was constructed. A NCBI protein BLAST of the 368 
DBD (residues 1 - 69) against the Protein Databank identified the P22 c2 phage 369 
repressor DNA-binding domain (PDB sequence file: 3JXB), meeting the criteria of well-370 
characterised and highest sequence homology (34%) (Fig. 7a). The P22 c2 phage 371 
repressor protein structure was used as a model in ProtMod for the structural analysis 372 
of the BcrR DNA-binding domain (Fig. 7b - d) [16]. The three-dimensional model 373 
predicts that five α helices make up the BcrR DBD (helices 1 - 4), with helices 2 (16 - 374 
25) and 3 (28 - 37) forming the HTH motif, and bordering helices 1 (3 - 13) and 4 (44 375 
- 53) providing structural support (Fig. 7a and 7b). It also suggests BcrR forms a 376 
homodimer at each set of inverted repeats and highlights a potential dimerisation 377 
interface between residues 40 - 61 (helix 4 and 5) (Fig. 7b). This observation 378 
hypothesises functional overlap between the DBD and OGD, and therefore indicates 379 
oligomeric status could play an important role in transitioning the DBD from an 380 
inactivated to activated conformational state in the presence of bacitracin.  381 
Virtual amino acid substitutions were carried out on the three-dimensional model for 382 
R11K and S33L using PyMOL (The PyMOL Molecular Graphics System, Version 1.7 383 
Schrödinger, LLC) (Fig. 7). An R11K substitution appears to disrupt a conserved salt 384 
bridge between R11 (R14 in model) and E36 (E39) and eliminate the hydrogen bond 385 
between R11 and L16 (I19 in model) in the DBD model (Fig. 7c and d). The R11 386 
residue is conserved among XRE-type HTH DNA-binding domains (R14 in P22 c2 and 387 
R10 in 434) (Fig. 7a), and previous investigations in the P22 c2 and 434 Cro repressor 388 
have shown that this residue provides structural support to the HTH motif (helices 2 389 
and 3) through the observed salt bridge (R11 - E36) and hydrogen bond (R11 - L16) 390 
(Fig. 7c) [18, 19]. Disrupting this interaction in the 434 phage repressor (R10M) 391 
loosens the core structure of the DNA-binding domain and alters the DNA-binding 392 
surface of the protein [20]. We therefore hypothesise that a less dramatic R to K 393 
change at position 11 allows the BcrR R11K mutant to retain its ability to bind to the 394 
bcrABD target promoter as observed in the EMSA (Fig. 7c); but propose, loss of the 395 
hydrogen bond between R11 and L16 and weakening of the R11 - E36 salt bridge may 396 
alter the DNA-binding surface upon activation by bacitracin, thereby affecting the 397 
ability of BcrR R11K to induce transcription of the bcrABD operon.  398 
The three-dimensional model predicts a S33L (S36 in model) substitution disrupts the 399 
direct hydrogen bond with the DNA phosphate oxygen due to the lack of a polar 400 
hydroxyl side group (Fig. 7c and d), which would suggest the loss of function in the 401 
S33L is likely due to inability to bind to the target promoter. However, the EMSAs show 402 
S33L retains its ability to bind and recognise the target promoter (Fig. 6d). We 403 
therefore hypothesise that some interactions at the protein and DNA interface are 404 
essential for constitutive binding to the DNA promoter, while others are essential for 405 
transducing bacitracin-dependent activation to the DNA promoter to allow initiation of 406 
transcription of bcrABD by RNA polymerase (RNAP).  407 
The mechanism of promoter activation by BcrR is unknown, however it is thought that 408 
upon binding of bacitracin BcrR undergoes a conformational change. This is thought 409 
to result in either a topological change in the bcrABD promoter exposing the core 410 
promoter elements to RNAP, or in recruitment of RNAP by the promoter-proximal 411 
dimer of BcrR [5]. Low-affinity protein-DNA operator complexes have previously been 412 
shown to reduce DNA-twisting [18, 21] therefore, it is conceivable that in the absence 413 
of either the R11 - L16 hydrogen bond, or the S33 - DNA hydrogen bond, BcrR is 414 
unable to transduce the signal from the bacitracin-binding site to the target promoter 415 
to allow exposure of the core promoter elements, and initiation of bcrABD expression. 416 
BcrR localisation to the cell membrane 417 
Membrane localisation is essential for BcrR function and therefore mutations in the 418 
transmembrane domain that confer a LOF likely result in a misfolded protein that is 419 
either displaced from the membrane, subjected to degradation, or insensitive to 420 
bacitracin. Two transmembrane domain mutants E179K and T183M were tested for 421 
cellular localisation, using BcrR WT and three mutants R11K, S33L, and G64D as 422 
controls. For these experiments, BcrR WT and mutants were expressed in E. coli as 423 
we have previously shown that functional BcrR localises to the membrane in this 424 
bacterium [4] and non-functional BcrR (membrane domain removed) localises to the 425 
cytoplasm [5]. Upon expression of BcrR WT and variants in E. coli cellular proteins 426 
were subsequently separated into membrane and cytosolic fractions. Fractions were 427 
analysed by SDS-PAGE and BcrR localisation probed by Western Blot (Fig. 8a and 428 
b). When the membrane fractions were run alongside the cytosolic (supernatant after 429 
ultracentrifugation) fraction, BcrR was clearly observed in the membrane fraction, and 430 
not in the cytosolic fraction (Fig. 8a). BcrR was found in the membrane fraction in all 431 
cases, confirming that membrane localisation does not play a role in either of the loss 432 
or gain of function BcrR mutants. 433 
BcrR is reported to directly detect bacitracin, but the bacitracin-binding site of BcrR 434 
has not been identified [5]. Transmembrane receptor proteins such as sensor kinases 435 
ApsS and PhoQ, which regulate resistance to cationic antimicrobial peptides 436 
(CAMPs), are known to detect target ligands through their extracellular domains [22–437 
24]. These proteins sense CAMPs at the membrane surface through an acidic 438 
extracellular loop that can vary in length from nine amino acids in ApsS to 145 in PhoQ, 439 
and while bacitracin is not a CAMP, it does have amphipathic properties [24, 25]. BcrR 440 
has two putative extracellular loops embedded in its C-terminal transmembrane 441 
domain. Seven LOF mutations were isolated in the TMD, with three (E179K, P180S, 442 
and T183M) clustered to the second extracellular loop. We have previously shown 443 
direct bacitracin-binding using tryptophan fluorescence, however this technique lacked 444 
the sensitivity to detect differences between WT and these LOF mutants (data not 445 
shown).  Nevertheless, we hypothesise the second extracellular loop of the 446 
transmembrane domain may serve as a potential bacitracin-binding site, exploiting the 447 
hydrophilic and hydrophobic properties of this region to aid in binding of the 448 
amphipathic bacitracin.  449 
AgrC binds its target peptide through a two-step process which involves initial non-450 
specific interactions in the hydrophobic pocket formed by the transmembrane helices, 451 
followed by specific hydrophilic interactions provided by the final extracellular loop [26, 452 
27]. We hypothesise bacitracin binding may trigger conformational changes that are 453 
transduced to the DNA-binding domain, via the oligomerisation domain that activate 454 
BcrR.  As the protein is constitutively bound to its target DNA, these conformational 455 
changes are then thought to change the local DNA topology and/or mediate direct 456 
interactions with RNAP [4, 5], leading to expression of bcrABD  and ultimately 457 
activation of bacitracin resistance.  458 
Conclusion 459 
We originally identified the bcr locus in a bacitracin-resistant clinical isolate of E. 460 
faecalis using a transposon mutagenesis screen, which has since been identified in 461 
other Gram-positive bacteria, such as Clostridium perfringens [3, 28]. Acquired 462 
bacitracin resistance in E. faecalis is mediated by an ABC transporter (BcrAB) and a 463 
novel regulatory protein, BcrR [3]. Here, we have carried out random mutagenesis on 464 
the high-level bacitracin resistance regulator BcrR to further our understanding of how 465 
it functions as a membrane-bound one-component system. Fifteen unique point 466 
mutations were identified in bcrR, distributed across all three putative functional 467 
domains, the N-terminal XRE-type DNA-binding domain, intermediate oligomerisation 468 
domain, and C-terminal transmembrane domain. Of these fifteen mutations, fourteen 469 
conferred a loss of BcrR function, and one a hyper-sensitive GOF. Previous work has 470 
established B. subtilis and E. coli as heterologous hosts for analysis of BcrR function 471 
and we employed these systems here for further analysis of five BcrR mutants [4, 5, 472 
12]. Two mutants were identified at the G64 locus, a G64S substitution that 473 
significantly reduced bacitracin-induced BcrR activation and a G64D substitution that 474 
significantly increased activation compared to the WT. This G64D substitution also 475 
allowed BcrR activation in the absence of bacitracin under xylose-inducible 476 
expression. We propose a model that suggests the presence of glycine at position 64 477 
plays a critical role in regulating BcrR activation, thereby allowing expression of the 478 
resistance operon bcrABD only in the presence of bacitracin (Fig. S7). We hypothesise 479 
that this may also explain why even subtle substitutions such as G64S significantly 480 
alter BcrR activity (Fig 3b).  Promoter activity assays were utilised to analyse 481 
transcription activation of the G64D gain of function mutant. They highlighted the 482 
importance of the oligomerisation domain- specifically G64 in regulating BcrR 483 
activation in the presence of bacitracin (Fig. S7 and Fig. 9). We showed that the DNA-484 
binding domain is not only important for binding the bcrABD promoter, but also for 485 
transducing and activating BcrR in the presence of bacitracin to allow initiation of 486 
bcrABD transcription by RNAP; and identified a potential bacitracin-binding site 487 
localised to a cluster of BcrR loss of function mutants at the second extracellular loop 488 
in the transmembrane domain (Fig. 9). BcrR was the first membrane-bound one-489 
component high-level antimicrobial resistance regulator identified in bacteria. This 490 
work builds on our previous work as it highlights the essentiality of each functional 491 
domain, and their co-operation, in order to articulate an effective response.  492 
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Table 1. Identification of BcrR loss and gain of function point mutations 598 
Mutant 
No. 
Domain 
Base 
No. 
Base 
change 
AA 
change 
Colour Status Frequency‡ 
        
BcrR8 DBD* 31 G-A R11K White OFF 2 
BcrR7 " 49 C-T T17M White OFF 1 
BcrR31 " 88 C-T T30I White OFF 1 
BcrR39 " 98 C-T S33L White OFF 1 
BcrR30 OGD# 124 C-T P42L White OFF 3 
BcrR17 " 151 C-T S51F White OFF 3 
BcrR21 " 189 G-A G64S 
Blue/ 
White OFF 1 
BcrR37 " 190 G-A G64D Blue ON 2 
BcrR10 TMD† 261 G-A G88R White OFF 2 
BcrR28 " 301 C-T P101L White OFF 1 
BcrR18 " 367 C-T T123I 
Blue/ 
White OFF 1 
BcrR1 " 421 G-A G141D White OFF 1 
BcrR16 " 534 G-A E179K White OFF 2 
BcrR11 " 537 C-T P180S 
Blue/ 
White OFF 1 
BcrR14 " 547 C-T T183M White OFF 3 
        
 599 
*DBD DNA-binding domain; #OGD oligomerisation domain; †transmembrane domain; 600 
‡the number of times a point mutation was isolated. 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
Fig. 1. Identification of bcrR mutants using a β-galactosidase reporter (PbcrA-609 
lacZ). Wild-type (WT) bcrR was cloned into the plasmid pXT under the xylose-610 
inducible promoter to form pXT-bcrR.  The B. subtilis strain SGB37 was transformed 611 
with pXT-bcrR, integrating upstream of the β-galactosidase reporter (PbcrA-lacZ), to 612 
form the positive control strain SGB43 (a). In the positive control, WT BcrR is 613 
expressed and activated upon the addition of xylose (Xyl; 0.2%) and bacitracin (Bac; 614 
0.5 μg ml-1) respectively. Activated WT BcrR subsequently binds the PbcrA promoter 615 
inducing expression of the β-galactosidase reporter, thereby producing blue colonies 616 
on LB agar plates containing Xgal (100 μg ml-1) (a). In a separate experiment, pXT-617 
BcrR plasmid DNA was mutagenised with hydroxylamine hydrochloride (HA), 618 
purified,and transformed into  SGB37 (b). Transformants were plated on LB 619 
spectinomycin (spec) selection agar and the resulting colonies were subsequently 620 
stamped onto LB agar plates containing a combination of Xyl, Xgal, and Bac. This was 621 
used to screen for BcrR loss of function (LOF) and gain of function (GOF) mutants 622 
using a modified blue/white protocol [12].  In the presence of WT or GOF BcrR colonies 623 
were blue, while BcrR LOF mutants were white (b). Colonies from Xyl/Bac/Xgal plates 624 
were stamped on Xyl/Xgal only plates to select for blue GOF mutants (b and c).  625 
 626 
 627 
Fig. 2. Mapping of LOF and GOF mutations on the BcrR protein. BcrR is a 204 628 
amino acid protein that consists of three putative functional domains: a N-terminal 629 
DNA-binding domain (light grey), an oligomerisation domain (medium grey), and a C-630 
terminal transmembrane domain (dark grey). Loss and gain of function mutations (X) 631 
were mapped to the BcrR protein sequence to visualise the distribution of mutations. 632 
 633 
 634 
 635 
 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
Fig. 3. BcrR activity in response to bacitracin using a PbcrA-lacZ reporter. 646 
Expression of the integrative PbcrA-lacZ promoter under the control of wild-type (WT) 647 
and mutant BcrR was measured using β-galactosidase activity. BcrR mutant activity 648 
is presented alongside WT and an empty vector negative control (NC) with data 649 
separated into putative functional domains: the DNA-binding domain (a), 650 
oligomerisation domain (b), and transmembrane domain (c). Data shown are the mean 651 
±SD (n = biological triplicate). Statistical significance was determined by performing 652 
an unpaired t-test of BcrR variants relative to WT at a bacitracin concentration of 1 μg 653 
ml-1 (p values: (*) <0.05, (**) <0.01, (***) <0.005).  654 
 655 
 656 
Fig. 4. BcrR wild-type (WT) and G64D activity in response to bacitracin in the 657 
presence of xylose using the PbcrA-luxABCDE reporter. BcrR expression is 658 
controlled by a xylose-inducible promoter cloned upstream of the BcrR gene in the B. 659 
subtilis heterologous host. BcrR WT and G64D mutant activity was monitored under 660 
high (+ xylose) by measuring luciferase luminescence. WT and G64D BcrR activity 661 
were compared at bacitracin concentrations of 0, 0.1, 0.5, and 1 μg ml-1 over a period 662 
of 120 min (a - d respectively). Data shown are the mean ± SD (n = biological 663 
quadruplicate). Statistical significance was determined by performing an unpaired t-664 
test of G64D relative to WT (p values: (*) <0.05, (**) <0.01, (***) <0.005, (****) <0.001). 665 
 666 
 667 
 668 
 669 
Fig. 5.  BcrR WT and G64D activity in response to bacitracin in the absence of 670 
xylose using the PbcrA-luxABCDE reporter. BcrR WT and G64D mutant activity was 671 
monitored under low BcrR expression at bacitracin concentrations of 0, 0.1, 0.5 and 1 672 
μg ml-1 using a PbcrA-luxABCDE reporter (a – d).  Activity was measured every 20 min 673 
for 120 min. Data shown are the mean ±SD (n = biological quadruplicate). Statistical 674 
significance was determined by performing an unpaired t-test of G64D relative to WT 675 
(p values: (*) <0.05, (**) <0.01, (***) <0.005, (****) <0.001). 676 
 677 
 678 
 679 
 680 
 681 
Fig. 6. DNA-binding profiles of WT and mutant BcrR to PbcrA. (a) A 92 bp DNA 682 
probe (PbcrA) was amplified from the bcrA promoter sequence and labelled with a 5’ 683 
fluorescent IRDye700 tag for visualisation. This probe contained the 69 bp sequence 684 
(bold) necessary for bcrA expression, including the set of inverted repeats (bold and 685 
italicised) that are essential for BcrR DNA-binding [4,5]. The DNA-binding profiles of 686 
BcrR wild-type (WT) (b) and five BcrR mutants R11K (c), S33L (d), G64D (e), E179K 687 
(f), T183M (g) to the bcrA target promoter were compared using electrophoretic 688 
mobility shift assays. PbcrA was incubated with BcrR WT and mutant proteoliposomes 689 
at protein: DNA molar ratios of 0:1 (lane 1), 25:1 (lane 2), 50:1 (lane 3), 125:1 (lane 4) 690 
the probe concentration. PbcrA was shifted in a BcrR concentration-dependent manner 691 
in BcrR WT and all five mutants; no shift was observed in the absence of BcrR (lane 692 
1) and no concentration-dependent shift was observed in the liposome only control 693 
(h). Lipid concentrations in lane 3 and 4 (h) are relative to lane 3 and 4 (b – g). Binding 694 
reactions were run on a 6% native PAGE gel at 350V for 25 min and visualised at 700 695 
nm. The gels presented here are a representative of shifts that have been repeated at 696 
least three times. 697 
 698 
 699 
 700 
 701 
Fig. 7. A three-dimensional model of the BcrR DNA-binding domain. The BcrR 702 
DNA-binding domain sequence was aligned with five well-characterised XRE-type 703 
HTH DNA-binding proteins (a). The P22 c2 phage repressor protein had the highest 704 
sequence homology with the BcrR DNA-binding domain. The P22 c2 structure was 705 
used as a model in ProtMod for the structural analysis of the BcrR DNA-binding 706 
domain. The DNA-binding domain consists of five α helices labelled 1-5 with helices 2 707 
and 3 composing the HTH motif (b). Interactions between BcrR mutant residues, other 708 
residues in the DNA-binding domain, and the target DNA promoter sequence were 709 
analysed using PyMOL (c). DNA-binding domain wild-type (WT) residues were 710 
substituted with their mutant counterparts to observe consequential changes to their 711 
WT interactions (d - f). 712 
 713 
 714 
 715 
 716 
Fig. 8. Localisation of BcrR WT and mutants to the cell membrane. Cell cytosolic 717 
(C) and membrane (M) fractions of the empty vector control (EV), BcrR wild-type (WT), 718 
and mutants R11K, S33L, G64D, E179K, and T183M from the protein localisation 719 
experiment (about 200-500 μg total protein) were run on a 12.5% SDS-PAGE gel 720 
alongside a BenchMark™ His-tagged protein ladder (a). Membrane fractions were 721 
rerun on a 12.5% SDS-PAGE gel for Western Blot analysis. BcrR WT and mutant 722 
protein contained a His6 C-terminal tag were subsequently probed for using an anti-723 
His antibody. BcrR was detected in all membrane fractions, except the negative control 724 
(EV) (b). 725 
 726 
 727 
 728 
 729 
 730 
 731 
 732 
Fig. 9. Schematic of bacitracin sensing and transcriptional activation by BcrR. 733 
BcrR directly senses bacitracin and elicits a response through activation and 734 
subsequent initiation of bcrABD transcription. In this model BcrR detects bacitracin 735 
through a putative bacitracin-binding site localised to the second extracellular loop of 736 
the C-terminal transmembrane domain (E179K, P180S, and T183M). BcrR is 737 
constitutively bound to the bcrA promoter (PbcrA) but requires bacitracin for activation, 738 
likely through a conformational change, such as the oligomerisation of the BcrR dimers 739 
to form an active BcrR tetramer. Glycine 64 (G64) likely plays an essential role in this 740 
process. The BcrR DNA-binding domain contains five putative α helices with a 741 
conserved XRE-type helix-turn-helix DNA-binding motif. R11 and S33 appear to have 742 
a crucial functional role in transducing the bacitracin activating signal to the DNA 743 
promoter. We hypothesise R11 and S33 are required for bacitracin-dependent 744 
changes in the local DNA topology, perhaps bending the DNA, to expose the binding 745 
site for RNA polymerase, allowing transcription of the bcrABD operon. 746 
 747 
 748 
 Fig. S1. BcrR WT and mutant transformation into the PbcrA-lacZ reporter strain B. subtilis 
SGB37. Clonal cultures of the PbcrA-lacZ reporter strain B. subtilis SGB37 were independently 
transformed with genomic DNA (gDNA) containing either the Pxyl-bcrR wild-type (WT) or mutant 
construct (S33L, G64S, G64D, and E179K). Transformants were plated on LBspec agar to select for 
gDNA containing the Pxyl-bcrR constructs.  Three colonies were chosen for each bcrR variant and 
streaked onto LBxyl,bac,xgal agar and incubated at 37˚C overnight. A representative photograph is 
presented here for each bcrR variant. The G64D gain of function mutant appears as blue colonies 
(a) which represents activated BcrR and are darker than the light blue WT colonies (b). The colonies 
of the loss of function mutants S33L (c), G64S (d), and E179K (e), appear white in colour, which 
represents a lack of active BcrR, i.e. loss of function. 
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Fig. S2. SDS-PAGE of purified wild-type (WT) and mutant BcrR protein. BcrRHis protein was 
purified in a series of sequential steps. Samples were taken after each step and run on a 12.5% 
SDS-PAGE gel after purification. (a) Lane 2: supernatant from the sodium cholate wash to ensure 
BcrR was not removed from the membrane. Lanes 3,4,5: Sequential DDM solubilisation of BcrR. 
Lanes 6,7: protein fractions from the non-specifically bound protein. Lanes 8-12: protein fractions 
from the BcrR peak (these fractions were pooled for dialysis). (b - f) Lanes 1-3: purified BcrR 
fractions from the second purification peak for each of the BcrR mutants. Lane 4 (b - f): shows BcrR 
after fractions are pooled and dialysed. 10 μl of sample were run regardless of total protein 
concentration (this equates to about 50 μg in the purified protein lanes).  
 
 
 
 
 
  
 
 
 
 
Fig. S3. BcrR protein concentration in reconstituted liposomes by SDS-PAGE gel 
electrophoresis. Wild-type (WT) BcrR protein and protein of BcrR mutants R11K, S33L, and G64D 
was purified and reconstituted into phosphotidyl choline liposomes. BcrR protein concentration in 
reconstituted proteoliposomes was determined by running 1.5 μl of BcrR WT (2), R11K (3), S33L 
(4), and G64D (5) proteoliposome on a 4 × SDS-concentrated 12.5% SDS-PAGE gel against a BSA 
standard at a range of 0.1 - 0.4 mg ml-1 (7 - 10). Protein size was determined by PageRuler™ protein 
ladder (1). A liposome only negative control was used to show absence of BcrR. 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig. S4. BcrR activity in response to bacitracin using a PbcrA-lacZ reporter. To confirm 
phenotypic observations of the new transformants, expression of the integrative PbcrA-lacZ promoter 
under the control of wild-type (WT) and mutant BcrR was measured using β-galactosidase activity. 
BcrR mutant activity is presented alongside WT. Data shown are the mean ±SD (n = biological 
triplicate). Statistical significance was determined by performing an unpaired t-test of BcrR variants 
relative to WT (p values: (*) <0.05, (**) <0.01, (***) <0.005). 
 
 
 
 
  
Fig. S5. Densitometric analysis of the free probe in the electrophoretic mobility shift assays. 
Band intensities are expressed relative (%) to the probe only band (Fig. 6. lane 1 (b – g)) in each 
electrophoretic mobility shift assay for each BcrR variant. White bars, no BcrR proteoliposomes (Fig. 
6. lane 1 (b – g)), light grey bars protein:DNA molar ratio of 25:1 (Fig. 6. lane 2 (b – g)), dark grey 
bars 50:1 (Fig. 6. lane 3 (b – g)), and black bars 125:1 (Fig. 6. lane 4 (b – g)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. S6. EMSA competition and controls for BcrR WT and PbcrA target probe. (a)  Wild-type 
(WT) BcrR proteoliposomes (P/L) were incubated with a fluorescently labelled PbcrA target probe and 
at increasing molar ratios of a non-labelled:labelled probe (5:1, 10:1, 20:1, 30:1, and 40:1 ) (lanes 1 
– 5). The competitor probe was the same length and nucleotide sequence as the labelled target 
probe (see methods). Labelled probe and BcrR (proteoliposomes) were at a constant concentration 
of 1.25 ng and 400 ng, respectively.  Fluorescently labelled bound probe was displaced at increasing 
concentrations concurrent with increasing non-labelled competitor probe. (b) Non-labelled 
competitor probe (1.25 ng) was incubated with increasing molar ratios of WT BcrR proteoliposomes 
(protein:DNA; 0:1, 50:1, and 125:1) (lanes 1 – 3). This confirmed the non-labelled competitor probe 
does not fluoresce. BcrR proteoliposomes only were shown to auto-fluoresce, with fluorescence 
increasing as liposome concentration increased (0, 100, 200, and 400 ng) (lanes 4 – 7). Binding 
reactions were incubated for 30 min at room temperature and then run on a 6% native PAGE gel at 
350V for 25 min and visualised at 700 nm. Data presented here are a representative of shift assays 
that have been repeated at least three times. 
 
 
 
 
 
 
 
 
 
 Fig. S7. A proposed model of G64D activation. Wild-type (WT) BcrR is constitutively bound to 
the bcrA target promoter but requires bacitracin for activation. BcrR gain of function mutant G64D 
can spontaneously activate and initiate expression from the bcrA promoter in the absence of 
bacitracin. This process relies upon high cellular concentrations of BcrR, as observed under a 
xylose-inducible promoter. In the presence of both xylose and bacitracin, G64D elicits a hyper-
sensitive response as a result of spontaneous activation, in addition to bacitracin-induced activation. 
A G64S substitution results in a defective BcrR, unable to effectively elicit a response to bacitracin. 
This is likely due to an inability to oligomerise upon bacitracin-binding.  
 
 
 
 
 
 
Table S1. Bacterial strains and plasmids 
Strain or Plasmid Description# Reference/Source 
   
B. subtilis   
SGB37 bceAB::kan amyE::pES601(PbcrA-lacZ); cmR kanR [1] 
SGB43 bceAB::kan thrC::pES701(pXT-bcrR; E. faecalis)  [1] 
 amyE::pES601(PbcrA-lacZ); specR cmR kanR  
SGB273 TMB1518 sacA::pNTlux101; cmR [1] 
SGB274 TMB1518 thrC::pES701 sacA::pNTlux101; cmR specR [1] 
BcrR_R11K SGB37 harbouring pES701 BcrRR11K; specR This study 
BcrR_T17M SGB37 harbouring pES701 BcrRT17M; specR This study 
BcrR_T30I SGB37 harbouring pES701 BcrRT30I; specR This study 
BcrR_S33L SGB37 harbouring pES701 BcrRS33L; specR This study 
BcrR_P42L SGB37 harbouring pES701 BcrRP42L; specR This study 
BcrR_S51F SGB37 harbouring pES701 BcrRS51F; specR This study 
BcrR_G64S SGB37 harbouring pES701 BcrRG64S; specR This study 
BcrR_G64D SGB37 harbouring pES701 BcrRG64D; specR This study 
BcrR_G88R SGB37 harbouring pES701 BcrRG88R; specR This study 
BcrR_P101L SGB37 harbouring pES701 BcrRP101L; specR This study 
BcrR_T123I SGB37 harbouring pES701 BcrRT123I; specR This study 
BcrR_G141D SGB37 harbouring pES701 BcrRG141D; specR This study 
BcrR_P180S SGB37 harbouring pES701 BcrRP180S; specR This study 
BcrR_E179K SGB37 harbouring pES701 BcrRE179K; specR This study 
BcrR_T183M SGB37 harbouring pES701 BcrRT183M; specR This study 
BcrR_G64D_lux SGB273 harbouring pES701 BcrRG64D; specR This study 
   
E. coli    
DH10B 
F- mcrAΔ(mmr-hsdRMS-mcrBC) φ80dlacZ ΔM15 ΔlacX74 
deoR  
[2] 
 recA1 araD139Δ(ara leu)7697 galU galK rpsL endA1 nupG  
C41(DE3) Uncharacterised mutant derivative from BL21(DE3) [3] 
C41 pTrc99A C41(DE3) harbouring expression vector pTrc99A; ampR This study 
WT C41(DE3) harbouring pBcrRHisWT; ampR This study 
R11K C41(DE3) harbouring pBcrRHisR11K; ampR This study 
S33L C41(DE3) harbouring pBcrRHisS33L; ampR This study 
G64D C41(DE3) harbouring pBcrRHisG64D; ampR This study 
E179K C41(DE3) harbouring pBcrRHisE179K; ampR This study 
T183M C41(DE3) harbouring pBcrRHisT183M; ampR This study 
   
E. faecalis   
AR01/DGVS AR01/DG cured of pJM02 bacR [4] 
   
Plasmids   
pES701 pXT-bcrR (wild-type) E. faecalis; specR [1] 
pTrc99A E. coli protein expression vector; ampR [5] 
pBcrRHisWT pTrc99A-bcrR wild-type; ampR This study 
pBcrRHisR11K pTrc99A-bcrR G33A mutation; ampR This study 
pBcrRHisS33L pTrc99A-bcrR C98T mutation; ampR This study 
pBcrRHisG64D pTrc99A-bcrR G192A mutation; ampR This study 
pBcrRHisE179K pTrc99A-bcrR G535A mutation; ampR This study 
pBcrRHisT183M pTrc99A-bcrR C548T mutation; ampR This study 
      
 
 
Table S2. Primers used in this study 
Name Sequence 5'-3' 
Used to 
amplify/create 
   
pXT-check fwd CCTTACCGCATTGAAGGCC bcrR 
pXT-check rev GTATTCACGAACGAAAATCGCC bcrR 
BcrRFwd AAATTTCCATGGAATTTAATGAAAAGCTACAA BcrRHisWT 
HisBcrRRev AATTTGTCGACTTAGTGGTGGTGGTGGTGGTGTTTCATTCCCATCTGCTT " 
BcrRR11KmutF AACAGCTTAAGACTGGAAAGAACTTAACGCAGGAACAACTT BcrRHisR11K 
BcrRR11KmutR TTTCCAGTCTTAAGCTGTTGTAGCTTTTCATTAATTT " 
BcrRS33LmutF CAGCCATTTTAAAATGGGAAAGCGGCAAGGGTTACCCTAAC BcrRHisS33L 
BcrRS33LmutR TCCCATTTTAAAATGGCTGTTCTTGATACATATAATTGCTC " 
BcrRG64DmutF TACTATCGGACGAAGAACTGATTACACTTGCCGAAACTGAA BcrRHisG64D 
BcrRG64DmutR AGTTCTTCGTCCGATAGTAGTTCATCTATGGTCACAGAAAA " 
BcrRE179KmutF CGGCAAGAAAACCCTATATAACGGTACTTGTATTTTTGCTG BcrRHisE179K 
BcrRE179KmutR ATATAGGGTTTTCTTGCCGCTAAAAAACAGACAGCCAA " 
BcrRT183MmutF CCTATATAATGGTACTTGTATTTTTGCTGTTAATCGGCAAG BcrRHisT183M 
BcrRT183MmutR ACAAGTACCATTATATAGGGTTCTCTTGCCGCTGCAAAAAA " 
bcrA_EMSA_F /5IRD700/CAT AAA ACC TTG AAA ATA GGC T PbcrA 
bcrA_EMSA_R GAA ACC TAC CGT CAC AAT G " 
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